Evidence map›Paper›PMID 34673648›Full record

Observational studyUrologia internationalis2022

Tadalafil 5 mg Once Daily Improved Each IPSS Subscore, QOL, and Nocturia in Elderly BPH Patients over 70 Years Old in a Real-World Clinical Setting.

Takahira Kuno, Kenji Tamura, Hideo Fukuhara, Satoshi Fukata, Shingo Ashida, Takashi Karashima, Kohji Sawada, Masaharu Yasuda, Hironobu Watanabe, Fumito Komatsu and 3 more

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Urologia internationalis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 1 country.

Takahira KunoDepartment of Urology, Kochi Medical School, Kochi University, Nankoku, Japan.
Kenji TamuraDepartment of Urology, Kochi Medical School, Kochi University, Nankoku, Japan.
Hideo FukuharaDepartment of Urology, Kochi Medical School, Kochi University, Nankoku, Japan.
Satoshi FukataDepartment of Urology, Kochi Medical School, Kochi University, Nankoku, Japan.
Shingo AshidaDepartment of Urology, Kochi Medical School, Kochi University, Nankoku, Japan.
Takashi KarashimaDepartment of Urology, Kochi Medical School, Kochi University, Nankoku, Japan.
Kohji SawadaDepartment of Urology, Kochi Prefectural Hata Kenmin Hospital, Sukumo, Japan.
Masaharu YasudaDepartment of Urology, Kochi Prefectural Aki General Hospital, Aki, Japan.
Hironobu WatanabeDepartment of Urology, National Hospital Organization Kochi Hospital, Kochi, Japan.
Fumito KomatsuDepartment of Urology, Tosa Municipal Hospital, Tosa, Japan.
Hajime KuroiwaIntegrated Center for Advanced Medical Technologies (ICAM-Tech), Kochi Medical School, Nankoku, Japan.
Motoaki SaitoDepartment of Pharmacology, Kochi Medical School, Kochi University, Nankoku, Japan.
Keiji InoueDepartment of Urology, Kochi Medical School, Kochi University, Nankoku, Japan.
Kōchi University · JPChikamori Hospital · JPKochi Medical School Hospital · JPMakino Botanical Garden · JPNational Hospital Organization Kochi National Hospital · JPSoka Municipal Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveNo reports have evaluated the treatment effects of tadalafil by age group in a positive, noninterventional observational study of Japanese men. The present study aimed to evaluate the treatment effects of tadalafil by age group in a positive, noninterventional observational study of Japanese men. We therefore divided patients into 2 groups about the age of 70 years and investigated the treatment effects of tadalafil regarding voiding and storage functions by age group.

methodsChanges from baseline in each parameter (International Prostate Symptom Score [IPSS], quality of life [QOL] score, Overactive Bladder Symptom Score [OABSS], and residual urine volume) at 4, 12, and 24 weeks after initiating tadalafil for benign prostatic hyperplasia (BPH) patients were compared between groups (50-69 years vs. ≥70 years). In addition, side effects of tadalafil were investigated by age group.

resultsIn the 50-69 years group, significant improvements from baseline were seen in IPSS total and QOL score for all time points. In addition, significant improvements in IPSS storage subscore from baseline were observed at the 4- and 24-week time points. In the ≥70 years group, significant improvements from baseline were seen in IPSS total, IPSS voiding and storage subscores, and QOL score at each time point.

conclusionsTadalafil 5 mg once daily appeared effective in clinical settings for elderly BPH patients even over 70 years old.

Indexed as

Lower Urinary Tract SymptomsNocturiaProstatic HyperplasiaAgedHumansMalePhosphodiesterase 5 InhibitorsQuality of LifeTadalafilTreatment OutcomePhosphodiesterase 5 InhibitorsTadalafilEvaluation by age groupLower urinary tract symptomsPhosphodiesterase 5 inhibitorProstatic hyperplasiaTadalafil

Identifiers

PMID34673648
OpenAlexW3206774409

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.